Based on the cell specificity of ER ligands on the modulation of DHT actions, ER ligands are categorized to three different categories (Table II), which would be informative for the development of ER ligands in the treatment of prostate cancer. The gene discussed is ESR1; the disease is Familial prostate cancer.